Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Colloidal bismuth tartrate is a bismuth-containing compound used primarily for the treatment of gastric and duodenal ulcers, as well as for the management of Helicobacter pylori (H. pylori) infections. It acts by forming a protective barrier over ulcerated areas in the stomach lining, shielding them from gastric acid and promoting healing. Additionally, it exhibits mild antibacterial activity against H. pylori and stimulates mucus and bicarbonate production in the stomach, further protecting mucosal surfaces. Colloidal bismuth compounds are often used in combination with antibiotics to eradicate H. pylori infection[5][6][8]. The mechanism involves both physical protection of ulcers and direct antimicrobial effects.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on colloidal bismuth tartrate.